Cargando…

Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma

Dabrafenib resistance is a significant problem in melanoma, and its underlying molecular mechanism is still unclear. The purpose of this study is to research the molecular mechanism of drug resistance of dabrafenib and to explore the key genes and pathways that mediate drug resistance in melanoma. G...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Guangyu, Yao, Zhen, Shen, Jiaofeng, Liu, Yulong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046546/
https://www.ncbi.nlm.nih.gov/pubmed/33880366
http://dx.doi.org/10.1155/2021/5524486
_version_ 1783678872541200384
author Gao, Guangyu
Yao, Zhen
Shen, Jiaofeng
Liu, Yulong
author_facet Gao, Guangyu
Yao, Zhen
Shen, Jiaofeng
Liu, Yulong
author_sort Gao, Guangyu
collection PubMed
description Dabrafenib resistance is a significant problem in melanoma, and its underlying molecular mechanism is still unclear. The purpose of this study is to research the molecular mechanism of drug resistance of dabrafenib and to explore the key genes and pathways that mediate drug resistance in melanoma. GSE117666 was downloaded from the Gene Expression Omnibus (GEO) database and 492 melanoma statistics were also downloaded from The Cancer Genome Atlas (TCGA) database. Besides, differentially expressed miRNAs (DEMs) were identified by taking advantage of the R software and GEO2R. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) and FunRich was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis to identify potential pathways and functional annotations linked with melanoma chemoresistance. 9 DEMs and 872 mRNAs were selected after filtering. Then, target genes were uploaded to Metascape to construct protein-protein interaction (PPI) network. Also, 6 hub mRNAs were screened after performing the PPI network. Furthermore, a total of 4 out of 9 miRNAs had an obvious association with the survival rate (P < 0.05) and showed a good power of risk prediction model of over survival. The present research may provide a deeper understanding of regulatory genes of dabrafenib resistance in melanoma.
format Online
Article
Text
id pubmed-8046546
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-80465462021-04-19 Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma Gao, Guangyu Yao, Zhen Shen, Jiaofeng Liu, Yulong Biomed Res Int Research Article Dabrafenib resistance is a significant problem in melanoma, and its underlying molecular mechanism is still unclear. The purpose of this study is to research the molecular mechanism of drug resistance of dabrafenib and to explore the key genes and pathways that mediate drug resistance in melanoma. GSE117666 was downloaded from the Gene Expression Omnibus (GEO) database and 492 melanoma statistics were also downloaded from The Cancer Genome Atlas (TCGA) database. Besides, differentially expressed miRNAs (DEMs) were identified by taking advantage of the R software and GEO2R. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) and FunRich was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis to identify potential pathways and functional annotations linked with melanoma chemoresistance. 9 DEMs and 872 mRNAs were selected after filtering. Then, target genes were uploaded to Metascape to construct protein-protein interaction (PPI) network. Also, 6 hub mRNAs were screened after performing the PPI network. Furthermore, a total of 4 out of 9 miRNAs had an obvious association with the survival rate (P < 0.05) and showed a good power of risk prediction model of over survival. The present research may provide a deeper understanding of regulatory genes of dabrafenib resistance in melanoma. Hindawi 2021-04-05 /pmc/articles/PMC8046546/ /pubmed/33880366 http://dx.doi.org/10.1155/2021/5524486 Text en Copyright © 2021 Guangyu Gao et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gao, Guangyu
Yao, Zhen
Shen, Jiaofeng
Liu, Yulong
Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
title Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
title_full Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
title_fullStr Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
title_full_unstemmed Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
title_short Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
title_sort identification of key mirnas in the treatment of dabrafenib-resistant melanoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046546/
https://www.ncbi.nlm.nih.gov/pubmed/33880366
http://dx.doi.org/10.1155/2021/5524486
work_keys_str_mv AT gaoguangyu identificationofkeymirnasinthetreatmentofdabrafenibresistantmelanoma
AT yaozhen identificationofkeymirnasinthetreatmentofdabrafenibresistantmelanoma
AT shenjiaofeng identificationofkeymirnasinthetreatmentofdabrafenibresistantmelanoma
AT liuyulong identificationofkeymirnasinthetreatmentofdabrafenibresistantmelanoma